Health

STAT+: Roivant says closely watched immune drug succeeded in new eye disease

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/10/2026, 12:06:24 UTC.

Briefings

Roivant's Priovant announced that its immune drug Lisraya demonstrated superior efficacy over placebo in treating non-infectious uveitis across two Phase 3 trials involving 371 patients. This approval could expand the drug's market beyond its current use in dermatomyositis, targeting a potential 70,000 to 190,000 patient population in the U.S. with over 40,000 already on similar therapies. Roivant plans to seek FDA approval in the first half of next year.

Key points

• Roivant's Priovant reported that its immune-modifying pill Lisraya was more effective than placebo in treating non-infectious uveitis.
• The Phase 3 trials included 371 patients and spanned a period of 371 patients.

Context

Roivant and its spinout Priovant announced Wednesday that their immune-modifying pill Lisraya was more effective than placebo in treating the inflammatory eye disease non-infectious uveitis. The results, from two Phase 3 trials spanning 371 patients, could unlock a new blockbuster market for Roivant.

Limitations

The evidence is limited to two Phase 3 trials involving 371 patients. The specific dates of patient enrollment and follow-up are not provided in the source. The estimated patient population range of 70,000 to 190,000 is a company estimate rather than a confirmed clinical trial count. The source does not specify the exact dates of the Phase 3 trials or the duration of the drug's efficacy in the trials.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/10/2026, 12:07:34 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiehes2anglcrc5gguxmhvw4kpgunz4hsy6ixhyjh77erbtxo4rhpu